Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - agents antinéoplasiques - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

bavarian nordic a/s - salmonella enterica sérovar typhi - gélule - supérieur ou égale à 2.10^9 cellules - pour une gélule > salmonella enterica sérovar typhi, souche ty21a (vivante, atténuée supérieur ou égale à 2.10^9 cellules - vaccins bactériens - classe pharmacothérapeutique : vaccins bactériens - code atc : j07ap01.vivotif est un vaccin oral qui stimule une réponse immunitaire contre un type de bactérie appelé salmonella typhi qui provoque la fièvre typhoïde. il est utilisé pour la protection contre la fièvre typhoïde chez les adultes et les enfants âgés de 5 ans et plus.comment agit vivotif, gélule gastro-résistanteles bactéries vaccinales contenues dans vivotif ont été modifiées de façon à ce qu’elles ne puissent pas provoquer la fièvre typhoïde mais stimulent quand même le système de défense naturel de l’organisme pour combattre les bactéries qui causent la fièvre typhoïde.autres types de maladies causées par des bactéries salmonellail existe de nombreux autres types de bactéries salmonella. la plupart de celles-ci provoquent des maladies accompagnées de diarrhée qui sont très différentes de la fièvre typhoïde. elles sont également moins graves. vivotif ne peut pas vous protéger contre les infections causées par ces autres types de bactéries salmonella.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

daiichi sankyo (schweiz) ag - metoprololi tartras, chlortalidonum - divitabs - metoprololi tartras (2:1) 200 mg, chlortalidonum 25 mg, excipiens pro compresso de la brume. - antihypertensivum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

emergent biosolutions berna gmbh - salmonella typhi la vie stamm ty 21a - capsules - salmonella typhi la vie stamm ty 21a min.2 mia. u., antiox.: e 300, color.: e 127, excipiens de la capsule. - immunisation active contre la fièvre typhoïde abdominalis, à partir de l'âge de 5. ans - les vaccins

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

macopharma - méthoxsalène 0,02 mg/ml - solution pour la préparation ex vivo de fractions sanguines - 20 µg/ml - méthoxsalène 0.02 mg - other immunostimulants

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bavarian nordic berna gmbh - salmonella typhi la vie stamm ty 21a - capsules - salmonella typhi viva stamm ty 21a min.2 mia. u., salmonella typhi inactivata stamm ty 21a, saccharum 7.9-44 mg, e 300, caseinum hydrolysatum, magnesii stearas, lactosum max. 176.4 mg, kapselhülle: gelatina, e 171, e 127, e 172 (flavum), e 172 (rubrum), Überzug: hypromellosi phthalas, diethylis phthalas, ethylenglycolum, pro capsula. - immunisation active contre la fièvre typhoïde abdominalis, à partir de l'âge de 5. ans - les vaccins

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

orion pharma ag - estradiolum - gel - estradiolum 0.5 mg ut estradiolum hemihydricum, carbomerum 974p, trolaminum, ethanolum 96 per centum 292.5 mg, aqua purificata, propylenglycolum 62.5 mg ad gelatum pro 0.5 g. - pour le dispositif de traitement de oestrogenmangelsymptomen - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

orion pharma ag - estradiolum - gel - estradiolum 1 mg ut estradiolum hemihydricum, carbomerum 974p, trolaminum, ethanolum 96 per centum 585 mg, aqua purificata, propylenglycolum 125 mg ad gelatum pro 1 g. - pour le dispositif de traitement de oestrogenmangelsymptomen - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

paxvax berna gmbh - capsules

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bavarian nordic a.s. - salmonella typhi, vivant, atténué 2 10*9 cfu/dose - gélule gastro-résistante - salmonella typhi - typhoid, oral, live attenuated